Background The adoptive transfer of chimeric antigen receptor (CAR)-T cells has emerged
as a potent immunotherapy against some hematological malignancies but not yet for …

Immunotherapy that is based on adoptive transfer of T lymphocytes, which are genetically
modified to express chimeric antigen receptors (CARs) that recognize tumor-associated …

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types
of hematological malignancies, but have shown limited efficacy in patients with glioblastoma …

For successful application of chimeric antigen receptor (CAR) T cell therapy in solid tumors,
major hurdles have to be overcome. CAR T cells have to cross the vascular barrier, which is …

We previously reported that tumor vessel-redirected T cells, which were genetically
engineered with chimeric antigen receptor (CAR) specific for vascular endothelial growth …

Background aims The vascular endothelial growth factor (VEGF)/vascular endothelial
growth factor receptor (VEGFR) signaling pathway plays an important role in angiogenesis …

Immunotherapies based on adoptive cell transfer are highly effective in the treatment of
metastatic melanoma, but the use of this approach in other cancer histologies has been …

Purpose: A delay in encountering the cognate antigen while in the circulation, and the
suboptimal costimulation received at the tumor site are key reasons for the limited activity of …

Engineering T cells to express chimeric antigen receptors (CARs) specific for antigens on
hematological cancers has yielded remarkable clinical responses, but with solid tumors …

Adoptive T cell therapies based on chimeric antigen receptors (CAR-T) are emerging as
genuine therapeutic options for the treatment of hematological malignancies. The observed …